Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Inside Amylin's Anti-Icahn Suicide Pact
- Amylin has adopted a financial suicide pact which, in the company's own words, may bankrupt the company if dissident investors Carl Icahn and Eastbourne Capital get a majority of directors elected at the May 27 shareholder meeting. The pact is described in a lawsuit brought by a...
- Blog posts 2009-04-01
Additional Resources
- Amylin Founder Resigns, Suggests Chairman Follow; Icahn and Eastbourne Likely Delighted
- The Amylin board of directors is crumbling in its resistance to insurgent investors Carl Icahn and Eastbourne Capital. Amylin founder Howard Greene resigned as director and wrote a letter suggesting that chairman Joseph Cook should also step down. Greene said he won’t vote for Cook because: A majority of...
- Blog posts 2009-04-10
- Amylin v. Eastbourne Slideshow Battle; It's All About the Stock Price
- Amylin and Eastbourne Capital, locked in a fight for control of Amylin's board of directors, have escalated their war in the only way that beancounters know how: duelling presentations. You can see Amylin's here and a summary of Eastbourne's here. Eastbourne has kept it...
- Blog posts 2009-05-06
- Amylin Q1: "Icahn Doesn't Know Who Our CEO Is"
- Amylin filed a sarcastic letter describing phone conversations it had with angry investor Carl Ichan over the past few days. "Sarcastic," because the final point in the letter which you can read here is this: Finally, on our call you asked, "Who is Dan Bradbury?" Dan Bradbury is Amylin’s...
- Blog posts 2009-04-20
- Amylin Battle Heats Up as Eastbourne Capital Touts Rival Directors' Slate to Icahn's
- Eastbourne Capital has proposed a five-member team of its own for Amylin's board. Carl Icahn proposed his own slate last week. Both sets of investors are unhappy with the company that has a joint venture with Eli Lilly on diabetes drug Byetta. Eastbourne said of its move:...
- Blog posts 2009-02-02
- Amylin Insists Byetta Doesn't Cause Cancer; Wall Street Doesn't Seem So Sure
- Amylin CEO Daniel Bradbury may be wishing that Novo Nordisk's failed competitor to its diabetes drug Byetta had actually been approved by the FDA. Had Novo's liraglutide passed muster, no one would have gotten the jitters over whether Byetta gives you cancer or not. At Amylin's conference...
- Blog posts 2009-04-21
- Why I'm Buying Amylin Now
- Trader Mark submits: I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals AMLN. This is one of the few biotechs I know pretty well, and have followed for quite a while - mostly...
- External links 2008-08-20
- Icahn Moves on Amylin; Will Lilly Step Up?
- BNET's 10-Q Detective, David Phillips, reports that Carl Icahn has filed papers to nominate a slate of directors for the board of Amylin, maker of diabetes drug Byetta. The last time Icahn interfered with a smaller company, ImClone, it ended up being bought by Eli Lilly. Here's...
- Blog posts 2009-01-30
- Amylin CEO Got 11% Pay Rise Despite Losses; Company Paid $355K for Lawyer to Move House
- Combined executive pay at Amylin rose 10.2 percent last year even though the company lost 50 percent more money than it did the year before, according to a filing with the SEC. Amylin has not made a profit in the last five years, despite its revenues going from zero to...
- Blog posts 2009-04-22
- EquityOutlook.Com announces stock evaluation ratings for Xybernaut, Telefonos De Mexico, Biolase Technology, Amylin Pharmaceuticals, and Triquint Semiconductor.
- M2 PRESSWIRE-31 December 2003-EquityOutlook.Com: EquityOutlook.Com announces stock evaluation ratings for Xybernaut, Telefonos De Mexico, Biolase Technology, Amylin Pharmaceuticals, and Triquint SemiconductorC1994-2003 M2 COMMUNICATIONS LTD RDATE:12312003 EquityOutlook.Com Announces Stock Evaluation Ratings for Xybernaut, Telefonos De Mexico, Biolase Technology, Amylin Pharmaceuticals, and...
- Research articles 2003-12-31
- Icahn Bruising For Proxy Battle With Amylin Management
- [caption id="attachment_248" align="alignleft" width="200" caption="Byetta"][/caption] Activist investor Carl Icahn announced in a regulatory filing with the Securities and Exchange Commission his intention to nominate a slate of five directors to the board of Amylin Pharmaceuticals at the drugmaker’s May 2009 annual...
- Blog posts 2009-01-29
- Amylin Shares Find Support, But Upside Still Limited
- Zacks.com submits: We have been cautious on Amylin Pharmaceuticals, Inc. AMLN since the beginning of 2008, and we are still unconvinced that LAR will be approved on its first cycle FDA review. However, with the shares trading at multi-year lows, and the stock down 70% over the past...
- External links 2009-03-24
- Amylin, Biogen Idec Stand to Benefit from Icahn Board Victories
- Vincent Fernando submits: Biogen Idec BIIB over-explained its drug development, then called for an extra long recess, in order to delay the shareholder vote whereby activist investor Carl Icahn was trying to repeat his success with Amylin AMLN Pharmaceuticals and add four representatives to Biogen Idec's board. It appears...
- External links 2009-06-16
- Icahn Racks Up Gains in ImClone, Motorola, and Amylin
- Lon Juricic submits: Activist investor Carl Icahn had a nice day yesterday. Here's why:Bristol-Myers BMY sent Mr. Icahn a letter presenting a $60 per share offer for ImClone Systems IMCL. Icahn is the Chairman of ImClone, and owns 11,669,544 shares of the biotech company. With shares of ImClone...
- External links 2008-08-01
- EquityOutlook.Com Announces Stock Evaluation Ratings for Xybernaut Corp, Telefonos De Mexico, Biolase Technology, Amylin Pharmaceuticals, Triquint Semiconductor.
- M2 PRESSWIRE-7 January 2004-EquityOutlook.Com: EquityOutlook.Com Announces Stock Evaluation Ratings for Xybernaut Corp, Telefonos De Mexico, Biolase Technology, Amylin Pharmaceuticals, Triquint SemiconductorC1994-2004 M2 COMMUNICATIONS LTD RDATE:01072004 SHREVEPORT, La. -- EquityOutlook.Com makes these short-term stock recommendations: Xybernaut Corporation (Nasdaq:XYBR)...
- Research articles 2004-01-07
- Martek Biosciences, Amylin Pharmaceuticals issue public offering and CytRx provides private placement.
- M2 PRESSWIRE-21 January 2005-FNWU: Martek Biosciences, Amylin Pharmaceuticals issue public offering and CytRx provides private placementC1994-2005 M2 COMMUNICATIONS LTD RDATE:01212005 Biotechnology industry news provided by Financial News USA (OTC: FNWU). Martek Biosciences Corporation (Nasdaq: MATK), today announced that it has...
- Research articles 2005-01-21
- Amylin: A Discounted Option on Byetta's Outcome
- Vincent Fernando submits: Amylin AMLN presents a stock opportunity with substantial optionality, and is currently in the sights of activist investor Carl Icahn. I believe Mr. Icahn may not only be trying to make himself a profit, but may also be trying to get Eli Lilly LLY a good...
- External links 2009-04-22
- Will Carl Icahn Come to Amylin's Rescue?
- Mike Huckman submits: Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals AMLN. The shares have plummeted from nearly $30 just three months ago to around $7 yesterday. But billionaire activist investor Carl Icahn apparently sees the stock as being on sale. At the end...
- External links 2008-11-17
- Stock on the Move for Monday: MEDP! June 9, 2008
- Stock Market Alerts' performance stock list includes: MedSpas of America, Inc. (PINKSHEETS: MEDP), Amgen (NASDAQ: AMGN), Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Dendreon Corp. (NASDAQ: DNDN).
- Research articles 2008-06-09
- www.smallcapstockwatch.com , Focus Stock Alert.
- M2 PRESSWIRE-13 June 2006-Iron Consulting: www.smallcapstockwatch.com , Focus Stock AlertC1994-2006 M2 COMMUNICATIONS LTD RDATE:13062006 Stocks To Watch: Material Technologies Inc. (OTCBB: MTNA), Oracle Corp. (NADAQ: ORCL), Texas Regional Bancshares Inc. (NASDAQ: TRBS), Amylin Pharmaceuticals Inc.(NASDAQ: AMLN), Focus Media Holding Ltd....
- Research articles 2006-06-13
- << Previous
- page 1 of 1
- Next >>
